Moderna Shares Trade Below Intrinsic Value Estimates Amid Analyst Caution

Moderna's stock closed at $43.99, showing a 36.8% return year to date and 28.0% over one year, set against a 74.7% decline over three years and a 75.8% decline over five years. The company, which became prominent during the COVID-19 crisis by introducing one of the first successful vaccines, specializes in messenger RNA (mRNA) therapies that prompt the body's cells to generate proteins that can help prevent or treat various illnesses.

A discounted cash flow model using a 2 Stage Free Cash Flow to Equity approach arrives at an estimated intrinsic value of approximately $37.86 per share. Compared with a recent share price of $42.23, this suggests the stock appears roughly 11.5% overvalued on this measure. The latest twelve month free cash flow is a loss of about $2.19 billion, and analyst-based projections in the near term also remain in loss territory before turning positive. By 2030, projected free cash flow is $312 million.

Moderna currently trades on a price-to-sales ratio of 8.49x. That sits below the broader Biotechs industry average of 11.28x, but above the peer group average of 7.65x. A Fair Ratio calculation for Moderna is 1.41x, which is the P/S level a valuation model suggests could be appropriate after weighing factors like earnings growth profile, profit margins, industry, market cap and specific risks. Against that 1.41x Fair Ratio, Moderna's current 8.49x P/S screens materially higher.

Moderna scores 1 out of 6 on valuation checks, meaning it screens as undervalued on 1 of 6 checks. The company's market capitalization stands at $21.09 billion.

Analysts maintained a Hold rating on Moderna. The analyst consensus on Moderna is a Hold with an average price target of $31.19, representing a 25.5% downside from current levels. One analyst maintained a Hold rating with a $40.00 price target.